Accuray and Samsung NeuroLogica Push Forward on CyberKnife Imaging
Accuray has signed agreements with Samsung NeuroLogica to work on volumetric imaging for the CyberKnife robotic radiosurgery system. The Royal Marsden will be the first clinical center to take part, and the partners will assess technical, clinical, and business prospects in stages. No commercial product has been announced, and any future offering would depend on further review and regulatory clearances.
Accuray, listed as ARAY, has moved its earlier non-binding imaging letter of intent with Samsung HME America into formal agreements. The work focuses on volumetric imaging for the CyberKnife robotic radiosurgery platform, with Samsung NeuroLogica contributing mobile CT and imaging know-how and Accuray contributing treatment delivery and motion management experience.
The Royal Marsden is named as the first clinical site worldwide in this phased effort. The partners will assess technical, clinical, and commercial possibilities, including potential workflows that respond to patient anatomy. No commercial offering exists yet, and future steps depend on review and regulatory clearances. The companies presented the collaboration at ASTRO in Boston.
If the collaboration yields cleared imaging tools, patients receiving robotic radiosurgery may benefit from treatment planning that accounts for anatomy changes, potentially improving precision and comfort. Clinicians and hospitals could gain workflow options, though adoption may depend on cost, training, and reimbursement. Accuray and Samsung NeuroLogica may strengthen their competitive positions, but no product is assured. Regulators and health systems may weigh evidence before broad use.